Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03032835 · ClinicalTrials.gov registry record
Partners Calciphylaxis Biobank
A clinical trial of End Stage Renal Disease and Chronic Kidney Diseases, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 300
- Enrollment target
- 1
- Study location
NCT03032835: Recruiting study of End Stage Renal Disease and Chronic Kidney Diseases, sponsored by Massachusetts General Hospital.
NCT03032835 is a study of End Stage Renal Disease and Chronic Kidney Diseases that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 300 participants, below the 830-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03032835, a study of End Stage Renal Disease and Chronic Kidney Diseases, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 1
- Study location
Study Summary
Calciphylaxis, a vascular calcification disorder, is a rare and serious disorder characterized by calcification of dermal arterioles. There are significant gaps in the understanding of the pathophysiology and risk factors for calciphylaxis. At present, there is no effective treatment. Uncertain pathobiology, rare incidence and lack of collaborative approach have been some of the major limiting factors towards treating calciphylaxis. The Partners Calciphylaxis Biorepository (PCB) aims to address these gaps within calciphylaxis research by utilizing existing and, when necessary, developing new infrastructure to support the consent of patients and the collection of dedicated samples for a calciphylaxis repository.
Primary Outcome
Skin lesions will be assessed by investigators at baseline (entry into study) and at 6 months to determine whether there is improvement. The investigators will determine clinical, laboratory and genetic predictors of this outcome in calciphylaxis patients.
Conditions Studied
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2017-01 |
| Est. Completion | 2030-12 |
What NCT03032835 shows while recruiting
NCT03032835 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 830-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (64% lower).
The record links to 4 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 0 interventions.
NCT03032835 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03032835 about?
NCT03032835 is a clinical study titled "Partners Calciphylaxis Biobank". Calciphylaxis, a vascular calcification disorder, is a rare and serious disorder characterized by calcification of dermal arterioles. There are significant gaps in the understanding of the pathophysiology and risk factors for calciphylaxis. At present, there is no effective treatment. Uncertain pat...
What is the current status of trial NCT03032835?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2017-01. Estimated completion is 2030-12.
What conditions does trial NCT03032835 study?
This clinical trial studies the following conditions: End Stage Renal Disease, Chronic Kidney Diseases, Calciphylaxis, Calcific Uremic Arteriolopathy.
Who is sponsoring clinical trial NCT03032835?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03032835 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03032835's enrollment target sits among peer trials
300 16th of 86 higher than 70 of 86 other End Stage Renal Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End Stage Renal Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
RECRUITING · NA
-
Drug Interaction Potential of Pro-Inflammatory Conditions
RECRUITING
-
PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis
RECRUITING
-
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
RECRUITING · NA
-
AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses
RECRUITING · Phase 1
-
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia